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Abstract
Background: In parts of India, Chandipura Virus (CHPV) has emerged as an encephalitis causing pathogen in both epidemic
and sporadic forms. This pediatric disease follows rapid course leading to 55–75% mortality. In the absence of specific
treatment, effectiveness of RNA interference (RNAi) was evaluated.
Methods and Findings: Efficacy of synthetic short interfering RNA (siRNA) or short hairpin RNA (shRNA) in protecting mice from
CHPV infection was assessed. The target genes were P and M genes primarily because important role of the former in viral
replication and lethal nature of the latter. Real time one step RT-PCR and plaque assay were used for the assessment of gene
silencing. Using pAcGFP1N1-CHPV-P, we showed that P-2 siRNA was most efficient in reducing the expression of P gene in-vitro.
Both quantitative assays documented 2logs reduction in the virus titer when P-2, M-5 or M-6 siRNAs were transfected 2hr post
infection (PI). Use of these siRNAs in combination did not result in enhanced efficiency. P-2 siRNA was found to tolerate four
mismatches in the center. As compared to five different shRNAs, P-2 siRNA was most effective in inhibiting CHPV replication. An
extended survival was noted when mice infected intracranially with 100 LD50 CHPV were treated with cationic lipid complexed
5 mg P-2 siRNA simultaneously. Infection with 10LD50 and treatment with two doses of siRNA first, simultaneously and second
24 hr PI, resulted in 70% survival. Surviving mice showed 4logs less CHPV titers in brain without histopathological changes or
antibody response. Gene expression profiles of P-2 siRNA treated mice showed no interferon response. First dose of siRNA at 2hr
or 4hr PI with second dose at 24hr resulted in 40% and 20% survival respectively suggesting potential application in therapy.
Conclusions: The results highlight therapeutic potential of siRNA in treating rapid and fatal Chandipura encephalitis.
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Introduction
Chandipura virus (CHPV), an emerging encephalitis-causing
pathogen in India belongs to family Rhabdoviridae and genus
vesiculovirus. Outbreaks of CHPV have been reported from the
states of Andhra Pradesh [1], Gujarat [2] and Maharashtra
[National Institute of Virology (NIV), unpublished data] with
mortality varying from 55–75% in children. In an endemic area,
sporadic disease has also been recorded [3]. CHPV has a negative
sense RNA genome of approximately 11.0 Kb encoding 5
different proteins; nucleocapsid (N) protein, phosphoprotein (P)
protein, matrix (M) protein, glycoprotein (G) protein and large (L)
protein. The P protein has important functions in the virus life
cycle, both in transcription and replication [4]
RNA interference (RNAi) is a post-transcriptional process
triggered by the introduction of double-stranded RNA (dsRNA),
which is subsequently cleaved by Dicer into 21–23 nt small
interfering RNAs (siRNA). The siRNAs are then unwound by
RISC (RNA induced silencing complex) in the presence of ATP.
The activated RISC binds and degrades target mRNA guided by
the single strand of the siRNA [5–12].
In recent years, RNAi has emerged as a powerful tool for gene
silencing with a potential for therapeutic use in viral infections
such as Human immunodeficiency virus (HIV) [13] Influenza
[14], Respiratory syncytial virus (RSV) [15], SARS coronavirus
[16] and Ebola virus [17].
Severalstudies have shown that the centralnervous system (CNS)
is also acquiescent to RNAi as in the case of brain cancer [18],
Spinocerebellar ataxia [19]. Intracranial injection of siRNA has
shown immense potential in suppressing encephalitis caused by two
flaviviruses, JEV (Japanese encephalitis virus) and WNV (West Nile
virus) [20]. Control of non-segmented negative-strand RNA virus
replication in culture cells by siRNA has been well documented
[21]. A recent study has shown inhibition of rabies virus replication
by multiple artificial microRNAs (amiRNA) in Neuro 2a cells [22].
Considering the recent emergence of a rapidly progressing viral
infection leading to encephalitis with high fatality proportion in
children from India and the absence of any specific treatment,
RNAi based interventions were explored to suppress CHPV
infection in mice.
Materials and Methods
Cells and Virus used in study
Human embryonic Kidney (HEK)-293 cells were used for the
siRNA studies and Vero E6 cells were used for the plaque assay.
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8615Chandipura Virus 034627, isolated during 2003 Andhra Pradesh
epidemic [1] was used throughout the study.
Cloning and expression of P gene of CHPV in pAcGFP1N1
P gene of CHPV was amplified by reverse transcriptase
– polymerase chain reaction (RT-PCR) using PFloF1 (59-
TCTCGAGCTCAAGCTCCACCATGGAAGACTCTCAACT-
AT-39) and PGFPR1 (59-CCGCGGTACCGTCGAATTGAAC-
TGGGGTTCAAG-39) primers without stop codon and cloned
into pAcGFP1N1 vector (named pAcGFP1N1-CHPV-P). HEK-
293 cells were transfected with 2 mg each of pAcGFP1N1 and
pAcGFP1N1-CHPV-P. Transfected cells were observed under
florescent microscope periodically to check the expression of green
fluorescent protein (GFP) fused CHPV P protein and confirmed by
western blotting using anti-GFP antibodies (Invitrogen, Carlsbad,
CA, USA).
Design and synthesis of siRNA
All CHPV sequences present in the GenBank [23] and the
sequences of the new isolates generated in the lab (NIV,
unpublished data) were used to design the siRNA. All siRNAs
were designed using HP OnGuard siRNA design. (Table 1 and
Fig 1). Four and 8 siRNAs were synthesized for P gene and M
gene respectively targeting cDNA (+) strand. Negative control
siRNA (ncsiRNA) with no significant homology to any known
mammalian gene was used as a non-silencing control in all RNAi
experiments and purchased from qiagen (Catalog number
1027280) and negative control plasmid (NCP) was used in shRNA
experiments (Ambion, USA).
(http://www1.qiagen.com/Products/GeneSilencing/SiRnaDuplexes/
HPGuaranteed.aspx).
Transfection of siRNA
For the transfection of siRNA, amaxa nucleofactor II device and
supplemented kit V solution was used as suggested by the
manufacturer. For transfection using HiPerfect reagent, HEK-
293 cells were seeded 12–16 hr before transfection in a six-well
plate (1610
5 per well). Lipid-siRNA complexes were prepared by
incubating 100 pmol of siRNA with HiPerfect reagent (QIAGEN,
Valencia, CA) in the appropriate volume as recommended by the
manufacturer. To determine transfection efficiency, P-2 siRNA
tagged with Alexa Fluor-647 was used (Qiagen, Valencia, CA).
P gene siRNA validation with pAcGFP1N1-CHPV-P
Cells were transfected with P gene siRNA (P-1 to P-4) at a
concentration of 100 pmol and 2 mg of target expressing plasmid
pAcGFP1N1-CHPV-P. 24 hr post transfection, cells were har-
vested and flow cytometry and real time one step RT-PCR were
carried out. For real time one step RT-PCR, RNA was isolated
using RNAeasy minikit (QIAGEN, Valencia, CA) as described by
Figure 1. Schematic representation of gene arrangement in CHPV and siRNAs used. P and M genes were targeted for siRNA synthesis. The
numbers were assigned arbitrarily and do not indicate location (refer table 1 for correct location of siRNA). Different siRNA used to determine
tolerance for mismatches using P-2 siRNA number in parentheses represent the positions at which mismatches were incorporated (For sequence of P-
2 siRNA mutants refer table 2).
doi:10.1371/journal.pone.0008615.g001
Table 1. Sequences of the siRNAs (target) located in P gene
[CIN0327R (AY614726)] and M gene (AF128868).
Name Sequences Location
P-1 AGCAATTGATAAAGAATTCAT 1968–1988
P-2 ACCGAATCACCTGGCTCCAAA 1894–1914
P-3 CAGTTCAATTGAAATGATGCA 2173–2193
P-4 GAGAGGAATTCCCAGCTATTA 1428–1448
M-1 ATGGAATATTCTTACAAACAA 633–653
M-2 AAGCTTCAGTATAAATGTGTA 337–357
M-3 ATGGAACAGCTCGATGGATTA 201–221
M-4 CAACACATGGCTGATTTCTAA 801–821
M-5 CCCGGTCAATTTCCGAGACGA 723–743
M-6 TGCGATCAATCCATTCAGAGA 369–389
M-7 CAGTGGATACATTGGGAAGAA 435–455
M-8 TCCATGATGTTTGTCCCAGAA 598–618
doi:10.1371/journal.pone.0008615.t001
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TM
(Promega, Madison, USA) enzyme was used. 500 ng of total RNA
was used for real time one step RT-PCR. Each real time one step
RT-PCR assay had at least two no amplification controls (NAC) in
which RT enzyme was substituted by DNase-RNase free water to
check for the DNA contamination.
P gene and M gene validation with CHPV
HEK-293 cells were infected with 360 plaque forming units
(PFU) of CHPV. Cells were transfected with 100 pmol of different
siRNAs at 2 hr PI. Cell supernatants were harvested 24 hr post
transfection, RNA isolated using QIAmp viral RNA minikit
(QIAGEN, Valencia, CA) and real time one step RT-PCR was
carried out as described earlier [24].
Effect of combination of siRNA on the replication of
CHPV
To determine the effect of combination of siRNAs on the
replication of CHPV, a concentration of 100 pmol of all the
siRNAs was used alone or in different combinations.
Real time one step RT-PCR, flowcytometry and plaque
assay to assess gene silencing
Total RNA from cells transfected with pAcGFP1N1-CHPV-P,
mouse brain samples and viral RNA from supernatant of CHPV
infected cells were subjected to real time one step RT-PCR as
described earlier [24].
For flowcytometry acquisitions were done using FACScalibur
(BD Bioscience) and analyses were performed using cell quest
software (BD Bioscience).
For plaque assay Vero cells were grown to near confluence in
24-well tissue culture plate. The cells were adsorbed with 10-fold
serially diluted supernatant containing CHPV at 37uC for 60 min.
Following adsorption, the cells were washed with PBS and fed with
1 ml of 2X MEM (Sigma, USA) along with 1.25% (w/v)
carboxymethyl cellulose (Sigma, USA). The cells were incubated
for 2 days and observed for plaques under an inverted microscope
and stained with crystal violet (0.1%) after fixing in 10% (v/v)
formal saline. The plaques were counted and the titer of the virus
was calculated as PFU/ml [25].
Tolerance for mismatches
To investigate the tolerance of RNAi system for mismatches in
the siRNA relative to target mRNA, different siRNAs with
mismatches at specific positions as shown in Table 2 and Fig 1
were designed.
Comparison of P-2 siRNA and P-2 short hairpin RNA
(shRNA) efficiency
To deliver the siRNA in shRNA format and to compare
efficiency of the siRNA and shRNA, the sequence of the P-2
siRNA was subjected to the link www.ambion.com/techlib/misc/
psilencer_converter.html. DNA oligos were synthesized and
named as pH1-P2 or pCMV-P2 depending upon the plasmid
promoter used for the expression of shRNA. Following a report
documenting hypersusceptibility of Dicer-1-deficient mice to VSV
infection as a result of impaired miR-24 and miR-93 expression
[26], we examined the contribution of miR-93 in the replication of
CHPV. Use of bioinformatics tools, RNA22 (http://cbcsrv.
watson.ibm.com/rna22_targets.html) and RNAhybrid (http://
bibiserv.techfak.uni-bielefeld.de/rnahybrid/submission.html) re-
vealed that CHPV P gene has two potential binding site for hsa-
miR-93. After confirmation, the role of miR-93 in the CHPV
replication was assessed by using the stem and loop of miR-93 in
different combinations using pSilencer 2.0 H1 neo vector
(Ambion, Applied Biosystems International, Foster City, CA)
and named pH1-mir-93 (hsa-miR-93 precursor sequence), pH1-
miR-93-P-2 (stem of miR-93 was replaced with P-2 siRNA) and
pH1-mir-93-P-2-30 (stem and loop of miR-93 was replaced with
P-2 siRNA and miR-30 respectively) was used. All the oligos were
synthesized by IDT, USA (Table 3). Sense and antisense oligos
were annealed and ligated to either pSilencer 3.1 H1 neo or
pSilencer 4.1 CMV neo vectors (Ambion, Applied Biosystems
International, Foster City, CA) as recommended by the manufac-
turer. All the clones were screened by restriction digestion and
confirmed by sequencing. Endofree maxi preps were made and
quantitated. Different shRNA expressing plasmids (5 mg) were co-
transfected individually with plasmid pAcGFP1N1-CHPV-P
(500 ng). 24 hr post transfection, cells were harvested, RNA
isolated and real time one step RT-PCR and FACS analysis were
carried out. Different shRNA expressing plasmids were individ-
ually transfected 24 hr at post transfection, cells were infected with
36 PFU/ml of CHPV. At 12 and 24 hr post PI, supernatants were
assayed for the presence of the CHPV by plaque assay and real
time one step RT-PCR.
Mouse infection
BALB/c mice aged 4–6 wks were used for all in vivo
experiments. These experiments were done in a biosafety level 2
animal facility at the NIV and were approved by the Institutional
Animal Ethics Committee (IAEC) for animal experimentations.
Mice were inoculated intracranially (ic) with CHPV. For
experiments using siRNA, siRNAs were complexed with HiPer-
fect
TM (QIAGEN, Valencia CA) according to the manufacturer’s
instructions and were administered at the same site once
simultaneously or at different intervals.
Mouse tissue preparation for real time one step RT-PCR,
gene expression and histopathology
Mice (n=3) were euthanized and brains/spleens were removed
and used in various experiments. For histopathology, the brain
samples were fixed in 10% neutral buffered formalin, embedded in
paraffin and 6-mm vertical sections were stained with hematoxylin
and eosin. For the quantitative assessment of CHPV replication in
mice brain using real time one step RT-PCR, RNA isolated using
Ribopure RNA isolation Kit (Ambion, USA) according to
manufacturer’s instructions and 500 ng of total RNA was used
per reaction [24].
Gene expression analysis using TaqMan Low Density Array
(TLDA), single-cell suspension of spleens were prepared by gently
Table 2. Mutant siRNAs used for determining tolerance of
mismatches in the P-2 siRNA.
S. No Name Nucleotide
Target sequence (Change is shown
in Bold)
1. P-2 (7) (A --T) CGAATCTCCTGGCTCCAAA
2. P-2 (8) (C--G) CGAATCAGCTGGCTCCAAA
3. P-2 (9) (C--G) CGAATCACGTGGCTCCAAA
4. P-2 (10) (T--A) CGAATCACCAGGCTCCAAA
5. P-2 (7–8) (AC-TG) CGAATCTGCTGGCTCCAAA
6. P-2 (9–10) (CT-GA) CGAATCACGAGGCTCCAAA
7. P-2 (7–10) (ACCT-GTTC) CGAATCGTTCGGCTCCAAA
doi:10.1371/journal.pone.0008615.t002
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spleens of the mice (n=3) from same group were pooled and
samples were run in duplicate on 7900-HT fast real time PCR
machine (Applied Biosystems International, Foster City, CA).
Data analysis was done using RQ software, with respect to control
(uninfected/untreated) and HPRT was used as endogenous
control.
Statistical analysis
Statistical analyses were done using XLSTAT 2009 program in
Excel 2007 software. Three independent experiments were
performed in triplicates. Results are expressed as means 6 SD.
Data were analyzed by one way ANOVA followed by Dunnett’s
test. For in vivo experiments, mice survivals were compared using
Log-rank (Mental Cox) and Gehan-Breslow-Wilcoxon tests and
GraphPad Prism software 5.0 evaluation version.
Results
Expression of P gene fused with GFP
For the initial rapid and efficient assessment of gene silencing, P
gene of CHPV was expressed with GFP as fusion protein.
Fluorescent microscopy and Western blotting confirmed expres-
sion of P protein fused with GFP. The molecular weight of the
fusion protein was approximately ,61.0 Kda. The molecular
weight of the GFP protein is 29.0 Kda and the molecular weight of
bacterial expressed P protein is 32.5 Kda [27]. Confocal
microscopy of HEK-293 cells transfected with pAcGFP1N1 and
pAcGFP1N1-CHPV-P showed cytoplasmic localization of fusion
protein
P gene siRNA validation with pAcGFP1N1-CHPV-P and
CHPV
At 24 hr post transfection, cells transfected with both P gene
siRNAs (P-1 to P-4) and target expressing plasmid pAcGFP1N1-
CHPV-P showed that P-2 siRNA could reduce the GFP
expression and P gene expression approximately by 80% (Fig 2a-
cc )( p ,0.05), whereas P-1, P-3 and P-4 were not very effective.
With respect to CHPV, efficacy of P-2 siRNA in reducing
replication was 2logs at 24 hr and 1log at 48hr (p,0.05) as
evidenced by plaque assay and real time one step RT-PCR
(Fig 2d). A dose response experiment using 10–300 pmol of P-2
siRNA and pAcGFP1N1-CHPV-P showed 100 pmol as optimum
concentration (Fig 2e).
Validation of M gene siRNAs with virus and comparison
with P-2 siRNA
M gene siRNAs (M1-M8) were tested with the virus and
efficiencies were compared with P-2 siRNA. The results showed P-
2, M-5 and M-6 to be equally potent in inhibiting CHPV induced
cytopathic effects as observed by phase-contrast microscopy (10X
magnification) (Fig 3a). Assessment of virus replication by plaque
assay and real time one step RT-PCR showed inhibition of CHPV
by 2logs and thus confirmed efficacy of all the three siRNAs
(p,0.05) (Fig 3b).
Effect of combination of siRNAs on the replication of
CHPV
Initially, we tried combinations of P-2, M-5 and M-6 siRNAs at
different concentrations (10, 25, 50, 100 and 200pmol of each
siRNA) against 36, 18 and 3.6 PFU/ml. Cells could not be
infected below 18PFU and no inhibition was observed at 10 and
25pmol concentrations of siRNAs. At 50 pmol, 1log and at 100
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depicts efficiency of P-2, M-5 and M-6 siRNAs when used alone or
in different combinations (P-2+M-5; P-2+M-6 and P-2+M-5+M6)
at 100pmol of each siRNA. In each case,. 2logs reduction in viral
titer as compared to controls was recorded (p,0.05). Infection
with CHPV at as low as 36 PFU/ml and as high as 3600 PFU/ml
did not alter the efficiency of the siRNA the reduction being 2logs
in all cases (Fig 4a-4c).
Tolerance for mismatches
P-2 siRNA could tolerate mismatches at single nucleotide
(positions 7, 8, 9 and 10) two adjacent mutations (at 7–8 and 9–10)
or four consecutive positions (at 7–10) as judged by both
pAcGFP1N1-CHPV-P and CHPV. Results showed at least 50%
P gene silencing (Fig 5a) (p,0.05) and 1log difference in the titter
of CHPV in mutant siRNA treated and control cells (Fig 5b)
(p,0.05).
Short hairpin RNA (shRNA) validation with pAcGPF1N1-
CHPV-P plasmid and with CHPV
Flowcytometery and real time one step RT-PCR documented
that P-2 shRNA expressed either from Pol III (pH1-P2) or Pol II
promoter (pCMV-P2) was as efficient as P-2 siRNA, when the
validation was done with pAcGFP1N1-CHPV-P. The reduction
was approximately 70% (Fig 6a) (p,0.05).
The silencing effectlasted till 12hr(Fig6b) (p,0.05) and was lost at
24hr when tested with CHPV. At 24hr there was no difference in the
treated and control cells. P-2 siRNA was used as a positive control
and showed activity similar to experiments conducted earlier.
Effect of intracranial administration of P-2 siRNA on CHPV
infection in mice
Transfection efficiencies of Alexa fluor-647nm-labeled P-2 siRNA
either with nucleofaction or Hiperfect reagent in HEK-293 cells were
83 and 62% respectively, as measured by flowcytometry. When the
cells infected with 360 pfu/ml CHPV were treated with P-2 siRNA,
Hiperfect was less effective than nucleofaction (2logs reduction at
12hr for both and 1log less at 24hr). For all in-vivo experiments
Hiperfect reagent was used for delivery of P-2 siRNA. As adult mice
are not susceptible to CHPV by peripheral route, intracranial route
was used for infection with the virus.
For the first experiment, 100LD50 CHPV was used. Simulta-
neous treatment either with P-2 siRNA (5 mg) or ncsiRNA (5 mg)
complexed with Hiperfect at the same site led to survival of 5–
7 days in former and 4–5 days in latter groups (Fig 7a) (p,0.006).
In another experiment, the virus dose was reduced to 10 LD50.
Mice received one (simultaneous) or two doses (0 and 24hr) of 5 ug
P-2 siRNA. In the first group, the animals showed extended survival
by 48 hr (,60% mice) followed by survival of one mouse (10%,
(p,0.001). Importantly, ,70% survival was recorded in mice
Figure 2. Validation of P gene siRNA using pAcGFP1N1-CHPV-P. (a) Fluorescent microscopic images of HEK-293 cells transfected with
different P gene siRNAs and plasmid pAcGFP1N1-CHPV-P. (b) P gene siRNAs validated by flowcytometry at the protein level (c) Reduced expression of
P gene mRNA by real time one step RT-PCR. (d) P gene validation with CHPV at different time points. (e) Effect of different doses of P-2 siRNA on the
expression of P gene as determined by flowcytometry and real time one step RT-PCR. Result are expressed as means 6 SD. * indicates significantly
different from control at p ,0.05 by Dunnett’s test.
doi:10.1371/journal.pone.0008615.g002
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accordance with the extended survival, the viral titres in the brain
tissue from mice treated with two doses of P-2 siRNA were reduced
by 4logs as compared to the control group (p,0.00031) (Fig 8).
Histopathology of the brains of ncsiRNA treated mice showed
typical features of viral encephalitis, such as meningeal vessels with
perivascular cuffing of lymphocytes (Fig 9a) and focus of gliosis &
demyelination in cortex (Fig 9b). Absence of brain inflammation or
neuropathology was obvious in P-2 siRNA-treated mice (Fig 9c
and 9d). Both mice groups were sacrificed on 5
th day post-CHPV
inoculation.
In order to rule out the induction of non-specific interferon
responses by P-2 siRNA, TLDA was performed. Gene expression
changes $2.5 fold were considered significant. Expression of IFN-
Figure 3. Validation of P-2 and M gene siRNA with CHPV. (a) Inhibition of CHPV induced cytopathic effects by siRNAs as observed by phase-
contrast microscopy (10X). (b) Effect of different siRNAs on the replication of CHPV as determined by real time one step RT-PCR and plaque
assay.Results are expressed as means 6 SD. * indicates significantly different from control at p,0.05 by Dunnett’s test.
doi:10.1371/journal.pone.0008615.g003
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PFU/ml. Results are expressed as means 6 SD. * indicates significantly different from control at p,0.05 by Dunnett’s test.
doi:10.1371/journal.pone.0008615.g004
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SOCS-1(,17-fold) and TNF (,5-fold) cytokines genes were
upregulated at 24hr PI. A significant reduction in the expression
of IFN-c (,2.5-fold) was noted at 48 and 96hr PI. IL-10 (,2.3-
fold) decreased at 48hr but increased at 96hr (6-fold) while SOCS-
1 decreased at all the time points (Fig 10a).
Expression of the chemokines genes (Ccl-2, .200-fold; csf2,
.10-fold and Ccxl-10, ,30-fold) and surface receptor molecules
(FasL, .2.5 fold and IL-2R, 4-fold) were upregulated at the initial
phase of infection, but decreased at later time points (Fig 10b, c).
None of the above changes observed in CHPV infected mice were
recorded in mice treated with P-2 siRNA or control mice receiving
P-2 siRNA complexed with Hiperfect. These data clearly show
that the protection offered by P-2 siRNA is specific and does not
reflect non-specific anti-viral response of IFN.
Anti-CHP-IgG antibodies were absent on days 7, 14 and 21
post-infection in P-2 siRNA treated, surviving mice.
Considering therapeutic importance, ability of P-2 siRNA to
clear established CHPV infection was also evaluated. Two doses of
siRNA (5 mg each 24hr apart) were found to give 40% and 20%
protection respectively when the treatment was given 2hr and 4hr
post-infection (p,0.0001) (Fig 11a, b).
Discussion
Following the recognition of emergence of CHPV as an
emerging pathogen causing rapid and high mortality in children
in India, being the national institute and considering restricted
spread of the virus, we undertook two approaches as probable
strategies to combat the infection, development of a prophylactic
vaccine [28] and siRNA administration as a probable therapeutic
agent (present study). We were able to identify a potent siRNA that
could protect mice from the lethal encephalitis even when the virus
was directly introduced in the target organ, the brain.
The first step was selection of the viral gene(s) to be targeted by
RNAi. We selected P and M genes as (1) P protein is indispensable
for the activity of L protein which functions as RNA dependent
RNA polymerase (RdRp) and (2) M protein is most lethal protein
encoded by rhabdoviruses on account of induction of cytopathic
effects and apoptosis in the cells [29].
Initially, a total of 12 siRNAs (4 for P gene and 8 for M gene)
were screened in-vitro. Co-transfection of pAcGFP1N1-CHPV-P
plasmid and all the P gene siRNAs identified P-2 siRNA as the
most potent in perturbing P gene expression (Fig 2). M gene
siRNAs were directly validated with the virus. P-2, M-5 and M-6
siRNAs were equally efficient in inhibiting CHPV induced
cytopathic effects (Fig 3). Replication inhibition in siRNA treated
cells was also confirmed by 2logs reduction in the virus titer as
evidenced by both plaque assay and real time one step RT- PCR
(Fig 3b). Unfortunately, use of combinations of effective siRNAs at
different concentrations did not yield additive benefit. A possible
explanation could be that cells have a limited capacity to assemble
the RNA-induced silencing complex (RISC) and siRNA’s compete
for the available RISC pool present in the cells [30]. Similar
observations have been reported for two respiratory viruses,
respiratory syncytial virus and parainfluenza virus [15,31].
To assess the specificity, inhibition of CHPV replication in P-2
and M-5/M-6 siRNA treated cells was assessed by G gene and P
Figure 5. Tolerance of RNAi for mismatches in the P-2 siRNA relative to target mRNA. Tested in vitro by using (a) pAcGFP1N1-CHPV-P
plasmid and (b) CHPV. Results are expressed as means 6 SD. * indicates significantly different from control at p,0.05 by Dunnett’s test.
doi:10.1371/journal.pone.0008615.g005
Figure 6. Validation and comparison of efficiency of P-2 siRNA with different P-2 shRNA. (a) Validation of different shRNA expressing
plasmids with pAcGFP1N1-CHPV-P by using FACS and real time one step RT-PCR and (b) Efficiency of different shRNA expressing plasmids in
modulating CHPV replication at 12hr and at 24hr determined by real time one step RT-PCR and plaque assay. Results are expressed as means 6 SD.
* indicates significantly different from control at p,0.05 by Dunnett’s test.
doi:10.1371/journal.pone.0008615.g006
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cases, 2logs reduction was recorded. This may reflect the
possibility of these siRNAs not only targeting their cognate
mRNA but also the positive (+) strand pre-genomic RNA thus
affecting overall replication of the virus.
So far, P gene / full genomes of CHPV isolated during 1965,
2003, 2004 and 2007 have been sequenced [23, our unpublished
data]. Percent nucleotide identity (PNI) for P gene varied from
99.7 to 95.8%. Thus the virus has not changed appreciably over a
period of 42 years. Despite the stable nature of the virus, tolerance
of mismatches in the P-2 siRNA was examined as this molecule
was to be evaluated in in-vivo experiments. Though mismatches in
the center of the siRNA duplex are most critical abolishing target
cleavage [32,33], introduction of different mismatches did show
Figure 7. Kaplan Meier Survival curve showing effect of different doses of virus and siRNA. (a) 100LD50 CHPV and single dose of P-2
siRNA was administered (n=5) (p,0.006). (b)1 0L D 50 of CHPV and single or two doses (n=10 for both) of P-2 siRNA (p,0.0001).
doi:10.1371/journal.pone.0008615.g007
Figure 8. Reduction in the levels of CHPV replication in mice brain. Each day, brain homogenates from 3 mice were taken for RNA isolation
and used for real time RT-PCR. Each symbol represents individual mouse. Data are shown only till all mice in control group died.
doi:10.1371/journal.pone.0008615.g008
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virus mutates, this siRNA will still be effective.
Considering several advantages offered by shRNA such as
requirement for low doses, long-term downregulation of the target
gene and an economic alternative to the siRNA, we also tried the
shRNA format. Though efficient silencing was observed at 12hr,
the efficacy was lost at 24hr (Fig 6b). This could possibly be
because of apoptosis and subsequent inhibition of host transcrip-
tion induced by M protein for both CHPV [34] and VSV [35]
infections. Similar to our findings, abrogation of DNA based
RNAi was found in apoptotic cells due to caspace-3 mediated
inactivation of Dicer-1 without affecting RISC dependent part of
RNAi [36]. Therefore, siRNA seems to be a better approach for
regulating CHPV replication especially because it is an acute
infection with rapid course and long-term treatment is not needed.
However, in a recent study, efficacy of shRNA was effectively
shown for the treatment of JEV encephalitis in mice by using
lentiviral vector. 100% survival was recorded when mice were
injected IC with pseudotyped RV-G lentiviral vector expressing
shRNA specific for JEV and challenged half an hour later with 4
LD50 of JEV at the same site [20].
With the encouraging in-vitro results, we attempted to evaluate
P-2 siRNA in a murine model. Availability and selection of
suitable delivery system was the key question. Although successful
use of naked siRNA targeting the pain-related cation channel
P2X3 to treat chronic neuropathic pain in a rat model is reported
[37], poor uptake by brain parenchymal cells was shown in other
studies [38,39]. Recently, a cationic lipid formulation, i-Fect
(Neuromics) was found to deliver siRNA into neuronal cells
without toxicity and could protect mice against viral encephalitis
caused by flaviviruses [20]. We used P-2 siRNA complexed with a
cationic lipid (Hiperfect) for delivery into brain.
Simultaneous administration of 5 mg P-2 siRNA and 100 or
10LD50 virus resulted in 48 and 96 hr delay respectively in the
appearance of symptoms and death (Fig 7a and b). One mouse
survived with the lower dose of the virus. Importantly, when two
doses 5 mg P-2 siRNA were administered 24 hr apart, 70% mice
survived. In this experiment, the first dose of siRNA was given
simultaneously with the virus. To examine the degree of protection
offered by siRNA when administered after the virus inoculation, a
different two dose schedule was tried. i.e., 2 or 4 hr and 24hr-post-
virus inoculation (Fig 11a and 11b). Survival was reduced to 40%
and 20% respectively. Considering the rapidity of CHPV
replication, these results are significant. If we could introduce
large amount of siRNA post-infection, survival of mice seems
likely. Due to the limitation of the volume, this could not be tried.
It is pertinent to note here that for JE virus, a single injection
containing 40ug of siRNA with JetSI/DOPE led to complete
protection [20]. We need to try different liposome formulations
encapsulating optimum concentration of P-2 siRNA for achieving
near 100% survival when administered after infection with the
virus at variable intervals.
For the siRNA dosing yielding optimum protection (2 doses,
24hr apart) additional parameters were evaluated. Daily monitor-
ing of CHPV titers in the brain by real time one step RT-PCR
(Fig 8) clearly showed 4logs reduction in mice treated with P-2
siRNA when compared to ncsiRNA treated controls. Histopath-
ological analysis demonstrated that P-2 siRNA treated mice brains
did not exhibit common features of viral encephalitis seen
exclusively in the control group (Fig 9). In order to prove that
Figure 9. Histopathology of mice brain treated with P-2 siRNA. Hematoxylin and eosin-stained vertical brain sections from control mice
treated with ncsiRNA and infected with CHPV (a, b) and P-2 siRNA treated mice on 5
th day PI (c, d) at indicated magnifications.
doi:10.1371/journal.pone.0008615.g009
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of survived mice at 7, 14 and 21 days after infection for the
presence of anti-CHP-IgG antibodies. Absence of such antibodies
demonstrated limited / no viral replication leading to no
development of humoral response (Data not shown).
To generate additional information on the immune response,
gene expression profiles were studied. For this, we used spleen and
not brain primarily because our aim was not to dissect out effect of
CHPV infection on the regulation of these genes in mice, but
limited to compare the expression levels of immune response genes
in among the siRNA treated and control mice receiving the same
dose of the virus. In this regard a paper by Koterski et al [40] on
Venazuelan equine encephalitis virus (VEEV) is noteworthy.
IFN has been shown to have antiviral effect both against VSV
[41] and CHPV [42] as evidenced by in-vitro and human studies
respectively. Fig 10a clearly documents excessive upregulation of
IFN gene in the early stages of the infection (24hr PI) followed by
drastic decrease. Thus, though IFN is produced in large quantities
to combat the infection, desired effect was not achieved leading to
death. Importantly, no elevation was recorded in virus-infected P-
2 siRNA treated as well as control mice receiving the vehicle
alone. IL-10, involved in the suppression of the protective immune
response was elevated in the initial phase and at the time of death.
This cytokine might be playing crucial role in the pathogenesis of
CHPV. The elevated expression of TNF and IL-1b were found to
decrease with time that is consistent with a previous report
documenting susceptibility of TNF-a and IL-1b knockout (KO)
mice to lethal HSV-1 encephalitis [43]. SOCS-1, the suppressor of
cytokine signaling gene playing a critical role in the negative
regulation of cytokine signaling was steadily decreasing after initial
elevation. These results are similar to a study with rabies virus
infection wherein downregulation of SOCS-1 gene was shown
[44].
The elevated levels of Ccl2 and Cxcl-10 suggest recruitment and
activation of dendritic cells, macrophages, neutrophills and other
white cells to the sites of infection. However, as TNF and IFN-c
are known to induce Cxcl-10, deceasing levels of TNF and IFN-c
correlate well with downregulation of Cxcl-10 in our study [45].
FasL and IL-2R were upregulated in the beginning of infection
and deceased further. FasL is known to induce apoptosis in brain
cells during viral encephalitis [46].
The gene profiling results clearly demonstrate that none of the
genes modulated during the course of CHPV infection were
affected in P-2 siRNA treated mice confirming that the siRNA did
not allow replication of CHPV (real time and histopathology also
scored the brains as negative for CHPV) and therefore did not lead
to the cascade of immune reactions leading either to recovery or
death. Absence of anti-CHP antibodies provides similar evidence.
In a nutshell, we report the identification of an efficient siRNA
that can potently protect mice against lethal encephalitis induced
by CHPV and utility of the cationic lipids for effective brain
delivery. This preliminary but important finding should be taken
to its logical conclusion by conducting additional studies
mentioned earlier including trial in rhesus monkeys.
Figure 10. Gene expression profiles of siRNA treated mice using TLDA. (a) cytokines genes, (b) chemokine genes and (c) cell surface
molecules in spleen of mice from 3 groups- (1) CHPV infected control (2) CHPV infected and P-2 siRNA treated and (3) Hiperfect + P-2 siRNA
inoculated control. Results are expressed as means 6 SD.
doi:10.1371/journal.pone.0008615.g010
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